A Study of JNJ-87890387 for Advanced Solid Tumors
Phase 1
200
about 4.6 years
18+
2 sites in MI, TN
What this study is about
This trial is testing a treatment called JNJ-87890387 in people with advanced solid tumors. The goal is to find the best dose of this medication and see how safe it is at that dose.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take JNJ-87890387
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity, Part 1: Number of Participants with Dose Limiting Toxicity (DLTs)
Secondary: Part 1 and Part 2: Area Under the Curve from Time Zero to Time tau (AUC[0-tau]) of JNJ-87890387, Part 1 and Part 2: Area Under the Curve from Time t1 to Time t2 (AUC[t1-t2]) of JNJ-87890387, Part 1 and Part 2: Duration of Response (DOR), Part 1 and Part 2: Maximum Observed Serum Concentration (Cmax) of JNJ-87890387, Part 1 and Part 2: Objective Response Rate (ORR), Part 1 and Part 2: Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-87890387